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154 Cystic ﬁbrosis and hypogammaglobulinemia: is there a role for
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T. Van Ackere1, K. De Boeck1, I. Meyts1, M. Proesmans1. 1University Hospital
Leuven, Department of Pediatrics, Leuven, Belgium
Introduction: High levels of IgG in Cystic Fibrosis (CF) are associated with more
severe chronic lung disease. Although there are no data on subnormal IgG levels
and prognosis, underlying humoral immunodeﬁciency could potentially aggravate
CF lung disease.
Objectives: To document retrospectively whether subcutaneous immunoglobulin
substitution (SCIG) had a positive inﬂuence on the clinical course in children with
CF and hypogammaglobulinemia (HG).
Methods: We analyzed the medical charts of 5 patients with CF and HG who
received SCIG between Jan 2010 and Dec 2010 because of frequent and severe
respiratory infections despite intensive CF treatment. Data up to 1 year before start
of SCIG were compared with data up to 1 year after start SCIG.
Results: All patients were homozygous for F508del. Median IgG z-score before
start SCIG was −3.11 (IQR −3.25; −2.96). Average days of antibiotic (AB) use
per month before and under SCIG was not different (23.3 vs 30 days) mainly due
to use of oral maintenance AB. There was a trend towards a reduced need for
intravenous AB under SCIG (1.8 vs 0 days/month). There was no reduction in
number of positive culture swabs after SCIG (25 vs 67%). Although BMI z-score
increased in 4 out of 5, this was not statistically signiﬁcant.
Conclusion: Based on our limited experience with SCIG in patients with CF and
HG, we cannot document a clear effect on respiratory outcome. This may be due
to the use of maintenance oral AB and lack of good outcome measures. These data
will be compared with data of 5 patients with CF and HG not receiving SCIG.
Further study on the etiology of HG in children with CF and need for treatment is
needed.
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Nasal NO (nNO) is used as screening test for Primary Ciliary Dyskinesia (PCD). nNO
and exhaled NO (FENO) are low in PCD and CF.
We studied the discriminate validity of nNO and FENO or their combination for the
diagnosis of PCD.
Patients with PCD, CF, asthma (A), humoral immunodeﬁciencies (HID) and healthy
controls (HC) were recruited. 6 nNO and 2 FENO measurements, using the chemilumi-
nescence analyzer Spiroware 3.0® (Eco Medics) were performed during slow exhalation
against a ﬁxed resistance. ATS/ERS criteria were achieved.
Results nNO − FENO
HC
(n = 24)
PCD
(n = 23)
CF
(n = 22)
Asthma
(n = 28)
HID
(n = 19)
Age (median-IQR) (yrs) 13.05
(6.83)
11.77
(7.35)
13.13
(7.46)
10.23
(4.88)
9.84
(5.76)
nNO (median-IQR) (ppb) 723.7
(236.9)
44.2
(112.1)
421.7
(371.1)
725.5
(637.6)
763.6
(693.9)
FENO (median-IQR) (ppb) 10.4
(9.7)
4.6
(3.9)
9.9
(23.6)
13.5
(24.7)
11.0
(12.1)
For nNO, median coefﬁcient of variation (CV) was 7%, similar in subgroups. nNO
differed between PCD and no PCD (p 0.0001) and between PCD and CF (p 0.0001).
nNO <270 ppb had a sensitivity of 91.3% and a speciﬁcity of 90.6% to diagnose PCD
in the total group (n = 116) and a sensitivity and speciﬁcity of 87.5% and 77.3% with
only PCD and CF included. nNO was similar in HID and HC (p 0.448). There was
overlap between PCD and CF, and even A, but almost no overlap between PCD and
HC and HID.
Compared to HC, FENO was lower in PCD (p 0.0001), but not in CF, A and HID.
FENO was lower in PCD than in CF (p = 0.005). To diagnose PCD, FENO <7.1 ppb
had a sensitivity of 90.9% and a speciﬁcity of 68.2%. Adding FENO values to nNO
values in composite scores did not improve discriminate validity.
nNO as well as FENO is signiﬁcantly lower in PCD than in CF. But for the diagnosis
of PCD, composite scores of FENO and nNO do not improve discriminate validity.
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Background: Infection with inﬂuenza viruses can cause signiﬁcant morbidity in
patients with Cystic Fibrosis (CF). In 2009, a novel Swine Flu strain (H1N1) resulted
in a pandemic and the WHO recommended that all patients with chronic illnesses
should be given both the Inﬂuenza and Swine Flu vaccines. We have previously
demonstrated that the Inﬂuenza vaccine uptake rate amongst CF adults was 75%
[1].
Aims: To assess Inﬂuenza and Swine Flu immunisation rates during the 2009−10
season within our adult CF cohort.
Methods: Retrospective questionnaires regarding immunisation status and reasons
for non-adherence were given to all patients who attended the CF clinic and ward
between November 2010 and February 2011.
Results: A total of 102/240 responses were received. 79/102 (78%) and 69/102
(68%) patients were immunised with the Inﬂuenza and Swine Flu vaccines, re-
spectively. Reasons for non-adherence included forgetfulness (23%), needle phobia
(5%) and being too unwell (9%). Interestingly, more patients declined the Swine
Flu vaccine for fear of side effects than the Inﬂuenza vaccine (22% vs 9%).
Conclusions: The immunisation uptake rate in this cohort was lower for Swine Flu
than for Inﬂuenza but still signiﬁcantly higher than for other clinical risk groups in
England (68% vs 37%) [2]. A further audit of the combined Inﬂuenza/Swine Flu
vaccine is planned later this year.
Reference(s)
[1] Wat D et al. J Cyst Fibros. 2010: 9, S117 (449).
[2] http://www.dh.gov.uk/en/Publicationsandstatistics (DH_114203).
